All In Biotech

Drug Trial Radar · NCT05028556

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of Y101D, a Recombinant Anti-PD-L1 and TGF-β Bispecific Antibody for Injection, in Patients With Metastatic or Locally Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Aug 6, 2021

Primary completion

Jul 5, 2024

Study completion Sep 9, 2024

Sponsor

Lead sponsor
Wuhan YZY Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 31, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.

Conditions

  • Metastatic or Locally Advanced Solid Tumors

Interventions

  • Cohort 1 of Y101DDrug

    Y101D, 1mg/kg, Q2W, intravenous infusion

  • Cohort 2 of Y101DDrug

    Y101D, 3mg/kg, Q2W, intravenous infusion

  • Cohort 3 of Y101DDrug

    Y101D, 10mg/kg, Q2W, intravenous infusion

  • Cohort 4 of Y101DDrug

    Y101D, 20mg/kg, Q2W, intravenous infusion

  • Cohort 5 of Y101DDrug

    Y101D, 30mg/kg, Q2W, intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: From the time of the first dose (Day 1) until the 2nd dosing (Day 28)
  2. Adverse Events according to CTCAE V5.0Time frame: Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Prevention Center, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.